Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine carcinomas shows efficacious results
9 Feb 2024
Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine carcinomas shows efficacious results
Trifluridine/tipiracil and bevacizumab combination gives a prolonged PFS compared to trifluridine/tipiracil monotherapy in mCRC
Durvalumab plus bevacizumab, added to TACE, shows benefit for unresectable hepatocellular carcinoma
Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC